NRIX - Latest News

Nurix Therapeutics, Inc. (NRIX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $2.81B. Beta to the broader market is 1.79.

The article list below shows the most recent NRIX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent NRIX Headlines

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade

defenseworld.net - Aug 11, 2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Royal Bank Of Canada r

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

globenewswire.com - Aug 4, 2026

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

globenewswire.com - Aug 4, 2026

Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated

Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum

zacks.com - Jul 23, 2026

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline pro

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

globenewswire.com - Jul 21, 2026

BRISBANE, Calif. , July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.

How News Affects NRIX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NRIX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked NRIX news questions

What is the latest NRIX news headline?

The most recent NRIX headline (Aug 11, 2026) is "Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the NRIX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What NRIX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual NRIX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.